-
-
-
-
-
-
-
Argus downgrades Pfizer (PFE), lowers earnings estimates on 'near-term headwinds'
-
-
-
-
-
-
-
Pfizer (PFE) Reports Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO
-
-
-
-
-
-
-
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
-
-
-
-
-
-
-
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
-
-
-
-
-
-
-
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
-
-
-
-
-
-
-
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
-
-
-
-
-
-
-
Arvinas (ARVN) and Pfizer (PFE) Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)
-
975,771 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All